Biomarkers and Event Patterns of Vascular Disease in Hemodialysis

Parathyroid hormone (PTH) remains the central biomarker to classify CKD-metabolic bone disease (CKD-MBD) in hemodialysis patients. While PTH-values are known to be associated with adverse outcomes, interventional studies have failed to show a benefit of pharmacological modulation of PTH levels on hard clinical outcomes. To address this gap, the investigators explored alternative markers of bone metabolism, vascular calcification and inflammation in association to prospective event patterns.

NCT Number	NCT07170761
Lead Sponsor	Medical University of Graz Collaborators: Elisabethinen Hospital, Landeskrankenhaus Feldkirch
Conditions	Vascular Disease, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
Enrollment	475 participants
Start Date	2022-10-15
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-05